PROGNOSTIC SIGNIFICANCE OF ELECTROCARDIOGRAPHIC PARAMETERS ASSOCIATED WITH METABOLIC CHANGES IN THE MYOCARDIUM (LITERATURE REVIEW)

Highlights

The main ECG parameters associated with cardiovascular mortality in metabolic cardiomyopathy are P-wave changes, QT prolongation, ECG signs of left ventricular hypertrophy, depression and ST segment elevation, T-wave changes. These simple ECG markers are valuable signs of an unfavorable prognosis in patients with myocardial metabolic disorders.

Abstract

Cardiovascular diseases (CVD) are the leading cause of death globally, one of the initial manifestations of these diseases are metabolic changes in the myocardium.   Risk stratification in a young population makes would make it possible to timely identify such conditions and prevent their development, as well as their further progression. Electrocardiography is an effective, reliable, accessible and inexpensive method used in clinical practice and research. The aim of this article was to review electrocardiographic (ECG) features associated with manifestations of myocardial metabolic disorders, the mechanisms underlying these associations, and to briefly describe the main research findings in this area and consider the implications for clinical practice. The material and methods were literature sources analyzing metabolic changes in the myocardium and their electrophysiological manifestations, the following databases were used to search for relevant articles: elibrary.ru, pubmed.ncbi.nlm.nih.gov, researchgate.net. The results of the analysis showed that the main changes in ECG parameters associated with cardiovascular mortality in metabolic cardiomyopathy are P-wave changes, QT prolongation, ECG signs of left ventricular hypertrophy, depression and ST segment elevation, T-wave changes. Thus, simple ECGs-markers remain valuable indicators of an adverse prognosis for patients with metabolic disorders of the myocardium.

1. Antropova O.N., Silkina S.B., Polyakova I.G., Perevozchikova T.V. Association of hemodynamic parameters and cardiovascular risk factors with cardiac remodeling in young patients with prehypertension and hypertension. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020;25(6):73-78. (In Russian) doi:10.15829/1560-4071-2020-3797

2. Viktorova I.A., Shirlina N.G., Stasenko V.L., Muromtseva G.A. The prevalence of traditional risk factors for cardiovascular disease in the Omsk region: data of the ESSE-RF2 study. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020;25(6):3815. (In Russian). doi.org/10.15829/1560-4071-2020-3815

3. Muromtseva G.A., Vilkov V.G., Shalnova S.A., Konstantinov V.V., Deev A.D., Evstifeeva S.E., Balanova Yu.A., Imaeva A.E., Kapustina A.V., Karamnova N.S., Shlyakhto E.V., Boytsov S.A., Nedogoda S.V., Shabunova A.A., Chernykh T.M., Belova O.A., Indukaeva E.V., Grinshteyn Yu.I., Trubacheva I.A., Efanov A.Yu., Astakhova Z.T., Kulakova N.V. The prevalence of wide QRS complex (≥110 ms) among the population, depending on sex, age and place of residence. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2020; 25(6):3478. (In Russian) doi: 10.15829/1560-4071-2020-3478

4. Tkacheva O.N., Kotovskaya Yu.V., Runikhina N.K., Frolova E.V., Naumov A.V., Vorobyeva N.M., Ostapenko V.S., Mkhitaryan E.A., Sharashkina N.V., Tyukhmenev E.A., Pereverzev A.P., Dudinskaya E. N. Clinical guidelines on frailty. Rossiyskiy zhurnal geriatricheskoy meditsiny = Russian Journal of Geriatric Medicine. 2020; 1: 11–46. (In Russian) doi.org/10.37586/2686–8636–1–2020–11–46

5. Polikutina O.M., Slepynina Yu.S., Karetnikova V.N., Mulerova T.A., Indukaeva E.V., Artamonova G.V. Prevalence of electrocardiographic changes in Kemerovo region according to the data of the ESSE-RF study. Kardiovaskulyarnaya terapiya i profilaktika=Cardiovascular Therapy and Prevention. 2019;18(1):120-126. (In Russian) doi.org/10.15829/1728-8800-2019-1-120-126

6. Kalinina A.M., Shalnova S.A., Gambaryan M.G., Eganyan R.A., Muromtseva G.A., Bochkareva E.V., Kim I.V. Epidemiological methods for identifying major chronic non-communicable diseases and risk factors during mass population surveys. Toolkit. Edited by prof. Boytsova S.A. M. 2015 - 96 p. (In Russian) Internet resource: http://www.gnicpm.ru

7. Prineas RJ, Crow RS, Zhang ZM. The Minnesota Code Manual of Electrocardiographic

8. Findings (including measurement and comparison with the Novacode). Standards

9. and Procedures for ECG Measurement in Epidemiologic and Clinical Trials. London:

10. Springer, 2010. p. 328. doi: 10.1007/978-1-84882-778-3

11. Muromtseva G.A., Vilkov V.G., Konstantinov V.V., Deev A.D., Oshchepkova E.V., Rotar O.P., Shalnova S.A. The prevalence of electrocardiographic abnormalities in the Russian population in the early 21st century (the ESSE-RF study). Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2018;(12):7-17. (In Russian) doi.org/10.15829/1560-4071-2018-12-7-17

12. Ilkhanoff L, Soliman EZ, Ning H, Liu K, Lloyd-Jones DM. Factors associated with development of prolonged QRS duration over 20 years in healthy young adults: the Coronary Artery Risk Development in Young Adults study. J Electrocardiol. 2012 Mar;45(2):178-84. doi: 10.1016/j.jelectrocard.2011.11.001. Epub 2011 Dec 23. PMID: 22197105; PMCID: PMC3542388

13. Lehtonen, Arttu O.; Langén, Ville L.; Porthan, Kimmo; Kähönen, Mika; Nieminen, Markku S.; Jula, Antti M.; Niiranen, Teemu J. Electrocardiographic predictors of atrial fibrillation in nonhypertensive and hypertensive individuals. Journal of Hypertension 36(9):p 1874-1881, September 2018. doi:10.1097/HJH.0000000000001760

14. Knudsen AD, Graff C, Nielsen JB, Thomsen MT, Høgh J, Benfield T, Gerstoft J, Køber L, Kofoed KF, Nielsen SD. De novo electrocardiographic abnormalities in persons living with HIV. Sci Rep. 2021 Oct 21;11(1):20750. doi: 10.1038/s41598-021-00290-x. PMID: 34675281; PMCID: PMC8531322

15. van Kleef MEAM, Visseren FLJ, Vernooij JWP, Nathoe HM, Cramer MM, Bemelmans RHH, van der Graaf Y, Spiering W; SMART-study group. Four ECG left ventricular hypertrophy criteria and the risk of cardiovascular events and mortality in patients with vascular disease. J Hypertens. 2018 Sep;36(9):1865-1873. doi: 10.1097/HJH.0000000000001785. PMID: 29878973

16. Muiesan ML, Salvetti M, Di Castelnuovo A, Paini A, Assanelli D, Costanzo S, Badilini F, Vaglio M, Donati MB, Agabiti Rosei E, de Gaetano G, Iacoviello L; Moli-sani Study Investigators. Obesity and ECG left ventricular hypertrophy. J Hypertens. 2017 Jan;35(1):162-169. doi: 10.1097/HJH.0000000000001121.PMID:27662187

17. Patel, N., Yaqoob, M.M. & Aksentijevic, D. Cardiac metabolic remodelling in chronic kidney disease. Nat Rev Nephrol 18, 524–537 (2022). https://doi.org/10.1038/s41581-022-00576-x

18. Pua CJ, Loo G, Kui M, Moy WL, Hii AA, Lee V, Chin CT, Bryant JA, Toh DF, Lee CH, Cook SA, Richards AM, Le TT, Chin CWL. Impact of Diabetes on Myocardial Fibrosis in Patients With Hypertension: The REMODEL Study. Circ Cardiovasc Imaging. 2023 Jul;16(7):545-553. doi: 10.1161/CIRCIMAGING.123.015051. Epub 2023 Jul 11. PMID: 37431660; PMCID: PMC10351902

19. Mustafina S.V., Vinter D.A., Rymar O.D., Scherbakova L.V., Sazonova O.V., Malutina S.K. Cardiometabolic risk factors in obese individuals and the risk of incident diabetes mellitus in 12-year prospective study. Ateroscleroz. 2021;17(1):52-61. (In Russian) doi.org/10.52727/2078-256X-2021-17-52-61

20. Lewis GA, Rosala-Hallas A, Dodd S, Schelbert EB, Williams SG, Cunnington C, McDonagh T, Miller CA. Impact of Myocardial Fibrosis on Cardiovascular Structure, Function and Functional Status in Heart Failure with Preserved Ejection Fraction. J Cardiovasc Transl Res. 2022 Dec;15(6):1436-1443. doi: 10.1007/s12265-022-10264-7. Epub 2022 Jul 5. PMID: 35790651; PMCID: PMC9722869

21. Pan K-L, Hsu Y-C, Chang S-T, Chung C-M, Lin C-L. The Role of Cardiac Fibrosis in Diabetic Cardiomyopathy: From Pathophysiology to Clinical Diagnostic Tools. International Journal of MolecularSciences.2023;24(10):8604. doi.org/10.3390/ijms24108604

22. Vepsäläinen T, Laakso M, Lehto S, Juutilainen A, Airaksinen J, Rönnemaa T. Prolonged P wave duration predicts stroke mortality among type 2 diabetic patients with prevalent non-major macrovascular disease. BMC Cardiovasc Disord. 2014 Nov 25;14:168. doi: 10.1186/1471-2261-14-168.PMID:25425321;PMCID:PMC4280689

23. Tereshchenko LG, Henrikson CA, Sotoodehnia N, Arking DE, Agarwal SK, Siscovick DS, Post WS, Solomon SD, Coresh J, Josephson ME, Soliman EZ. Electrocardiographic deep terminal negativity of the P wave in V(1) and risk of sudden cardiac death: the Atherosclerosis Risk in Communities (ARIC) study. J Am Heart Assoc. 2014 Nov 21;3(6):e001387. doi: 10.1161/JAHA.114.001387.PMID:25416036;PMCID:PMC4338733

24. Mozos I, Caraba A. Electrocardiographic Predictors of Cardiovascular Mortality. Dis Markers. 2015;2015:727401. doi: 10.1155/2015/727401. Epub 2015 Jul 16. PMID: 26257460; PMCID:PMC4519551

25. Timoshenko N.A., Ragino Yu.I., Pushkina O.V., Chernyavskii A.M., Tcimbal S.Yu., Voevoda M.I. Electrophysiological signs of myocardial damage associated with the metabolic syndrome and its components in men with coronary atherosclerosis. Ateroscleroz. 2016;12(1):19-27. (In Russian)

26. Ragino Yu.I., Timoshenko N.A., Chernjavskyi A.M., Tcimbal S.Yu., Scherbakova L.V., Voevoda M.I. Relationship of metabolic syndrome components with electrocardiographic biomarkers of metabolic cardiomyopathy in men with coronary atherosclerosis. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2015;(4):68-72. (In Russian) https://doi.org/10.15829/1560-4071-2015-4-68-72

27. Timoshenko N.A. Electrophysiological signs of myocardial damage associated with components of metabolic syndrome and poor prognosis in men with coronary atherosclerosis. bstract of thesis…cand. med. sci. Novosibirsk, 2015. (In Russian)